Medical devices — US PTAB Patent Cases
522 decisions indexed
Page 8 of 18 · 522 total
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
Terumo BTC, Inc v.Haemonetics Corporation
Terumo BCT has filed a post‑grant review petition challenging all 30 claims of Haemonetics’ plasma‑collection patent, arguing anticipation, obviousness, lack of written description, and patent‑ineligible subject matter. The petition relies on multiple prior‑art references covering blood‑fractionation and calculation methods.
Terumo BTC, Inc v.Haemonetics Corporation
Terumo BCT has filed a corrected PGR petition challenging Haemonetics' plasma‑collection patent (US 12,324,873). The petition alleges anticipation, obviousness, lack of written description, and patent‑ineligible subject matter. The Board must decide whether to institute the review.
Terumo BCT, Inc. v.Haemonetics Corporation
Terumo BCT petitions the PTAB to invalidate Haemonetics' plasma‑collection patent, asserting obviousness, lack of written description, and patent‑ineligible abstract ideas.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
Aesthetic Management Partners has petitioned the PTAB for Inter Partes Review of HydraFacial’s 9,550,052 microdermabrasion patent, asserting that all 17 claims are obvious over a combination of prior‑art devices.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
The USPTO Board granted institution of Inter Partes Review (IPR2025-01169), allowing the petitioner to proceed to trial against the challenged patent.
iRhythm Technologies, Inc. v.Welch Allyn, Inc. et al.
iRhythm Technologies withdrew its IPR challenge to Welch Allyn's cardiac monitoring patent. The Board granted the motion, ending the proceeding before institution.
iRhythm Technologies, Inc. v.Welch Allyn, Inc. et al.
iRhythm Technologies petitions the PTAB to invalidate five claims of Welch Allyn’s wearable ECG monitor patent, asserting obviousness over several prior‑art references. The petition highlights examiner oversight and argues that discretionary factors favor institution.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health petitions the PTAB to institute an IPR and invalidate all 20 claims of Worcester Polytechnic’s ‘362 patent covering PPG motion‑artifact detection, citing obviousness over Chon ‘947, Mollerus, and Simon. The petitioner also argues that discretionary denial is inappropriate under §314(a) and §325(d).
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard and Medline Industries jointly filed a motion asking the PTAB to keep their settlement agreement confidential and separate from the patent record for U.S. Patent 11,684,347 covering urinary catheters.
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard and Medline filed a joint PTAB motion to keep their settlement agreement confidential under §317(b). The request seeks to separate the agreement from the patent file and limit its disclosure to federal agencies only.
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard’s IPR challenge to Medline Industries’ patent 11,661,220 was terminated after the parties settled before trial. The Board granted the joint motion to terminate and kept the settlement agreement confidential.
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard and Medline have jointly filed a motion asking the PTAB to keep their settlement agreement confidential under 35 U.S.C. § 317(b). The request seeks to separate the agreement from the patent file and limit disclosure to federal agencies only.
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard seeks an IPR of Medline’s ’347 patent covering urinary catheter trays, challenging claims 1‑8, 10‑11, 13‑20 as obvious over multiple prior‑art references. The petition argues that discretionary factors do not favor denial and requests institution.
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard has filed an IPR petition seeking to invalidate Medline’s 11,661,220 catheter‑kit patent, asserting that all challenged claims are obvious over multiple prior‑art references.
C.R. Bard, Inc. et al. v.Medline Industries, LP
C.R. Bard seeks PTAB institution of an IPR to cancel Medline’s 11,661,219 catheter‑kit patent, arguing that every claim is obvious over a suite of prior‑art references.
Revvo Technologies, Inc. v.Cerebrum Sensor Technologies, Inc.
The USPTO Director has initiated a sua sponte review of the Board’s decision to institute inter partes review of Revvo Technologies’ challenge to Cerebrum Sensor Technologies’ patent. The review focuses on claim construction issues raised by the petitioner.
Samsung Electronics Co. Ltd. et al. v.OS - NEW HORIZON PERSONAL COMPUTING SOLUTIONS LTD.
Samsung Electronics seeks Director review of a PTAB decision that denied institution of an IPR against its life‑signs detector patent. The petition alleges examiner error, improper reliance on settled expectations, and due‑process violations. A stay of the parallel district‑court case is also argued.
Medtronic, Inc. v.Moskowitz Family LLC
Medtronic has filed an IPR petition seeking to invalidate claims 8, 9, 13, and 17‑21 of U.S. Patent No. 12,011,367, which cover a zero‑profile expandable intervertebral spacer. The petition relies on the Palmatier patent as prior art to argue anticipation and obviousness.
Zepp Health Corporation v.University of Connecticut
Zepp Health and the University of Connecticut entered a settlement that resolves all disputes over U.S. Patent 10,278,647. The parties jointly moved to terminate the pending IPR before the Board made an institution decision.
LifeVac, LLC v.DCStar Inc.
LifeVac has filed an IPR petition seeking to invalidate DCStar’s 11,478,575 patent covering an anti‑choking suction device. The petition relies on Chinese reference Zhongnan and Korean reference Yuchang to argue obviousness of all 17 claims and urges the Board not to deny institution under §§ 314(a) and 325(d).
LifeVac, LLC v.DCStar Inc.
LifeVac, LLC's IPR petition against DCStar Inc. was denied by the PTAB after the Board found insufficient evidence of unpatentability. The decision hinged on a prior art challenge regarding an inventor-originated public disclosure (IDEAR) that predated one key reference.
Anthony Inc. v.ControlTec, LLC
ControlTec seeks director review of the PTAB’s decision not to institute an IPR against its 18‑year‑old cochlear‑implant patent. Anthony Inc. counters, asserting the Director acted within discretion and that a material error involving the Carter reference exists.
Therabody, Inc. v.DataFeel, Inc. et al.
Therabody has filed a post‑grant review petition seeking cancellation of DataFeel’s 12,036,174 patent covering percussive massage devices. The petition alleges obviousness over multiple prior‑art references and a lack of written description and enablement. It also argues the Board should not invoke the Fintiv discretionary denial provision.
Therabody, Inc. v.DataFeel, Inc. et al.
Therabody's Post-Grant Review petition against DataFeel was denied by the PTAB after failing to demonstrate a likelihood of unpatentability for claim 4. The Board rejected grounds based on obviousness (103) and lack of enablement/written description (112).
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial have jointly moved to terminate IPR2025-00453 after reaching a settlement that resolves all disputes over HydraFacial's facial treatment patent.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial jointly filed a motion asking the PTAB to keep their settlement agreement confidential and separate from the IPR record, citing statutory confidentiality protections.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. and HydraFacial LLC settled their inter partes review disputes, leading the PTAB to terminate both IPRs before institution. The settlement agreement is treated as confidential business information.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. petitions the PTAB to cancel HydraFacial's 11,446,477 skin‑treatment patent, alleging obviousness over several prior‑art references.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial jointly filed a motion asking the PTAB to keep their settlement agreement confidential and separate from the patent file, invoking 35 U.S.C. §317 and related regulations.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.